INTRODUCTION

In connection with the breeding of highly productive livestock and the introduction of various biotechnological methods of its programmed reproduction, the problem of intrauterine embryo death is currently of particular relevance due to the large economic losses associated with reduced fertility and milk production (Bonadonna, 1969; Milovanov and Sokolovskaya, 1984; Lenchenko et al., 2007; Shirasuna et al., 2015). At the same time, embryonic mortality, reaching 30-40% or more, is the dominant reason for reducing the intensive development of the dairy cattle breeding industry and its profitability (Spencer, 2007; Dulger, 2012; Chaudhary and Purohit, 2012; Brooks et al., 2014).

Pathology of pregnancy takes an important place in the structure of antenatal (intrauterine) mortality causes in cows, defined in scientific literature and clinical practice as an intrauterine embryo and fetal growth retardation syndrome (IGR), manifested by a discrepancy in their size to the gestation period. According to literature data,
it is registered in 34.4–37.6% of cows (Tefera et al., 2001; Zhao et al., 2008). The manifestation of this syndrome has a negative effect not only on fetal survival, but also on the viability of newborns, on the morphofunctional development of their organs and systems of digestion, respiration and reproduction, on metabolism and endocrine system, and also reduced fertility and productivity (Demmers et al., 2001; Wu et al., 2006; Lenchenko et al., 2017; Suleymanov et al., 2018).

In the polyfactorial etiology of early embryo death and developmental delay, oxidizing stress, metabolic intoxication and the associated endocrine insufficiency of the sex glands and hypoprogesteronemia act as determining factors (Safonov, 2011; Lyalichkina et al., 2012; Spenser and Hanser, 2015; Basavaraja et al., 2017; Ealy and Wooldridge, 2017). Existing methods for preventing embryonic mortality are based on compensating the deficit in the body of inseminated animals with progesterone by its subcutaneous administration or by activating its endogenous synthesis with injections of gonadoliberins or gonadotropins (Klinsky et al., 1987; Chomaev and Kolodiev, 2003; Baitlesov, 2007; Romano et al., 2007).

In this regard, the issue of developing new and improving existing methods of preventing embryonic development disorders in cows is of particular relevance.

**The Aim of Research**

To study the effectiveness of pharmacological agents (progesterone, progestag, follymag, selemag, interferon-tau) for the prevention of early embryogenesis disorders in cows.

**Material and Methods**

The studies were carried out in 2018 under in OOO VS (village settlement) Vyaznovatovka (Nizhnedevitsky District, Voronezh Region) and ZAO Slavyanskoe (Verkhovskovsky District, Oryol Region) on black-and-white cows with an average annual milk production of 5.5–7.5 thousand kg with tie-up and yard housing at various times after calving. The study of the effectiveness of methods for the prevention of fetal mortality and fetal developmental delay was carried out on 81 cows, divided according to the principle of analogues into six groups.

The cows of the first group (n = 13) were intramuscularly injected with 2.5% progesterone oil solution at 5-6 and 12-14 days after insemination at a dose of 4 ml.

Animals of the second group (n = 15) were injected intramuscularly with the drug progestamag at 5-6 and 12-14 days after insemination at a dose of 2 ml.

Cows of the fifth group (n = 12) were injected with bovine recombinant interferon-tau three times between 12-14-16 days after insemination, 5 ml each.

Animals of the sixth group (n = 17) served as negative control - without drug administration.

Evaluation of the effectiveness of methods for preventing intrauterine growth retardation and mortality of embryos and fetuses was carried out at 30-32 and 60-65 days after insemination by ultrasound. Ultrasound studies were performed using an EasyScan scanner equipped with a 7.5 MHz linear sensor.

The diagnosis of embryonic losses was carried out by transrectal echographic examination of cows in the dynamics of becoming pregnant: for 38–45 days - the presence of an embryo in the cavity of the uterus and its absence in 60-65 days of pregnancy.

Diagnosis of intrauterine growth retardation syndrome in cows was carried out retrospectively. During ultrasound scanning and determination of fetometric indicators for 38–40 days of gestation, the embryo’s length is within 12–16 mm and the body diameter is 7–9 mm or for 60–65 days - the length of the fetus is within 25–45 mm and the body diameter is 12 -16 mm, was diagnosed with the syndrome of embryo and fetus delayed development in cows (Hansen et al., 2017).

Blood samples were taken from animals included in the experiment for morphological, biochemical and immunological studies. Hemomorphological blood analysis was performed on a ABX Micros 60 hematology analyzer, biochemical studies were performed on a Hitachi-902 analyzer, in accordance with the Methodological Guidelines for the Use of Biochemical Methods for Examining the Blood of Animals (Retzky et al., 2005). Immunological parameters, including bactericidal (BSA), lysozyme (LSA) serum activity, total immunoglobulins, circulating immune complexes, phagocytic activity of leukocytes (PAL), phagocytic number (PN), phagocytic index (PI) were determined using standard and unified methods in accordance with the Guidelines for the evaluation and correction of the immune status of animals (Shakhov et al., 2005).

The content of progesterone in the serum was determined...
on the day of insemination and on the 38th to 45th day of gestation with the use of reagents for the enzyme immunoassay for the determination of progesterone in the serum (ZAO NVO Immunotech).

The digital material was subjected to mathematical processing using the software package Statistica 6.0.

RESULTS AND DISCUSSION

Under the physiological conditions of embryo formation, progesterone levels sufficient to support the implantation processes are provided by the production of trophectoderm of the interferon-tau embryo, which has anti-luteolytic properties through the suppression of estrogen receptors and oxytocin in the endometrium and the blockade of prostaglandin F2α production (Lamming et al., 1995; Demmers et al., 2001; Basavaraja et al., 2017; Ealy and Wooldridge, 2017; Imakawa et al., 2017; Seleznev et al. 2017). Interferon-tau allows female ruminants to receive a signal about the presence of pregnancy. The maximum concentration of interferon-tau in ruminants reaches on the 17th day of pregnancy, and then decreases by 20–22 days (Spencer, 2007; Kose et al., 2016; Forde and Loner-}

Prevention of early embryogenesis disorders in cows was carried out using the following pharmacological agents: progesterone oil solution, progestag, follymag, selenium-containing oil — selemag, and bovine recombinant interferon-tau.

It was revealed (Table 1) that in the negative control group, fetal growth retardation syndrome was registered in 33.3% of fertilized cows, intrauterine death - in 16.7%. The use of progesterone oil solution is accompanied by a decrease in embryonic mortality by 1.2 times and a syndrome of delayed development of the embryo and fetus - by 2.3 times. A higher preventive efficacy (60.0%) showed a method using a prolonged form of progesterone, a progestag, the use of which is accompanied by the absence of cases of intrauterine embryo death and a reduction in fetal growth retardation syndrome by 3.0 times.

The use of gonadotropic follymag is accompanied by a decrease in embryonic mortality by 1.8 times and fetal growth retardation syndrome - by 3.7 times. Improving the effectiveness of gonadotropic drugs is provided by the additional inclusion in the scheme of prevention of selenium-containing drug selemag. The combined use of follymag and selemag provides an efficiency of 61.5%.

The most effective was the use of bovine recombinant interferon-tau - 66.7%. Three-time introduction of interferon-tau reduces the cases of intrauterine embryo death by 1.5 times compared with the negative control and the syndrome of delayed development - 3.0 times.

It should be noted that methods of preventing early embryogenesis disorders in cows using the prolonged form of progesterone - progestamag, bovine recombinant interferon-tau, or the combined use of the gonadotropic drug follymag and selenium-containing medication were most effective.

It was established that in the negative control group, the content of progesterone by 30–45 days of gestation increases by 30.5 times as compared with the first day of insemination.

At the same time, after applying progesterone oil solution, its concentration in 38–45 days of gestation is 16.4% higher compared with animals from the negative control group.

Pregnancy after the application of the prolonged progestamag proceeds against the background of an increased content of progesterone, the level of which is 11.9% higher than after a double injection of the progesterone oil solution and 30.3% (P < 0.01) than in intact animals. After applying follymag and selemag, the content of progesterone is higher by 19.7% compared to the cows from the negative control group. The highest concentration of progesterone in the first 1.5 months of pregnancy was after using bovine recombinant interferon-tau, which is 52.2% higher than that of intact animals.

Thus, pregnancy after the use of progestogenic and gonadotropic drugs, as well as interferons, proceeds against the background of an elevated progesterone level in serum. The progesterone level reaches to 16.4–52.2% higher in comparison with animals from the negative control group.

Differences in the content of progesterone in the blood serum of cows in the application of methods for preventing disorders of embryonic development were reflected in the results of echographic studies of the size of the corpus luteum, the length of the embryo and fetus in the first two months of pregnancy (Table 3).

It has been established that double application of progesterone oil solution contributes to an increase in the size of the corpus luteum gestation, which in 30–32 days of gestation exceed the same compared to intact animals by 18.7% (P < 0.05), and in 60–65 days - by 21.8%.
**Table 1:** The effectiveness of methods for the pharmacological correction of early embryogenesis disorders in cows

<table>
<thead>
<tr>
<th>Group</th>
<th>Number of cows</th>
<th>Fertilized Intrauterine death</th>
<th>Fetal developmental delay syndrome</th>
<th>Stayed pregnant %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 group</td>
<td>13</td>
<td>7 cows 53.8%</td>
<td>1 cow 14.3%</td>
<td>46.2</td>
</tr>
<tr>
<td>2 group</td>
<td>15</td>
<td>9 cows 60.0%</td>
<td>0 cow 0.0%</td>
<td>60.0</td>
</tr>
<tr>
<td>3 group</td>
<td>11</td>
<td>6 cows 54.5%</td>
<td>1 cow 9.1%</td>
<td>45.5</td>
</tr>
<tr>
<td>4 group</td>
<td>13</td>
<td>8 cows 61.5%</td>
<td>0 cow 0.0%</td>
<td>61.5</td>
</tr>
<tr>
<td>5 group</td>
<td>12</td>
<td>9 cows 75.0%</td>
<td>1 cow 11.1%</td>
<td>66.7</td>
</tr>
<tr>
<td>6 group</td>
<td>17</td>
<td>6 cows 35.3%</td>
<td>1 cow 16.7%</td>
<td>29.4</td>
</tr>
</tbody>
</table>

**Table 2:** The content of progesterone in the blood serum of cows in the prevention of fetal development disorders, nmol / l

<table>
<thead>
<tr>
<th>Group</th>
<th>Days of pregnancy</th>
<th>Insemination day</th>
<th>38-45</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 group</td>
<td>1,17±0,08</td>
<td>41,9±1,9</td>
<td></td>
</tr>
<tr>
<td>2 group</td>
<td>0,88±0,06</td>
<td>46,9±2,6**</td>
<td></td>
</tr>
<tr>
<td>3 group</td>
<td>0,95±0,09</td>
<td>39,8±2,1</td>
<td>**</td>
</tr>
<tr>
<td>4 group</td>
<td>0,95±0,07</td>
<td>43,1±2,2**</td>
<td></td>
</tr>
<tr>
<td>5 group</td>
<td>1,24±0,08</td>
<td>54,8±2,4**</td>
<td></td>
</tr>
<tr>
<td>6 group</td>
<td>1,18±0,11</td>
<td>36,0±2,3</td>
<td></td>
</tr>
</tbody>
</table>

**Table 3:** The size of the corpus luteum of pregnancy and the length of the embryo and fetus in the prevention of early embryogenesis disorders in cows, mm

<table>
<thead>
<tr>
<th>Group</th>
<th>Days of pregnancy</th>
<th>30-32</th>
<th>60-65</th>
</tr>
</thead>
<tbody>
<tr>
<td>The size of the corpus luteum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 group</td>
<td>16,5±1,1’</td>
<td>22,9±1,6</td>
<td></td>
</tr>
<tr>
<td>2 group</td>
<td>19,7±1,3”</td>
<td>27,1±1,2”</td>
<td></td>
</tr>
<tr>
<td>3 group</td>
<td>14,9±0,9</td>
<td>20,7±1,2</td>
<td></td>
</tr>
<tr>
<td>4 group</td>
<td>18,5±0,9’</td>
<td>25,4±1,5’</td>
<td></td>
</tr>
<tr>
<td>5 group</td>
<td>19,2±1,2”</td>
<td>26,5±1,7”</td>
<td></td>
</tr>
<tr>
<td>6 group</td>
<td>13,9±0,8</td>
<td>18,8±1,1</td>
<td></td>
</tr>
</tbody>
</table>

| Crown-rump length of fetus |       |       |
| 1 group | 18,7±1,1”          | 55,7±3,9 |
| 2 group | 20,5±1,2”          | 74,2±4,8” |
| 3 group | 17,9±1,1           | 54,1±4,1 |
| 4 group | 20,7±1,1”          | 69,4±3,7” |
| 5 group | 23,7±1,3”          | 75,6±5,3” |
| 6 group | 15,1 ±0,7          | 49,2±2,1 |

The use of prolonged form of progesterone - progestamag provides an increase in the size of the corpus luteum of pregnancy, which is 19.9% more in 30-32 days compared with the use of progesterone and by 41.7% (P <0.01) than in the negative control, at 60-65 days of gestation, respectively, by 18.3 and 44.1% (P <0.01).

An increase in the size of the corpus luteum of pregnancy had a beneficial effect on the size of the developing embryo and fetus.

Exogenous administration of progesterone in the early stages of pregnancy had a positive effect on the development of the embryo and fetus, which was manifested by an increase in length of 13.2-23.8% (P <0.01) in comparison with the negative control. The use of a prolonged progestamag provided an increase in the crown-rump length in comparison with intact animals by 35.8-50.8% (P <0.001). The use of follymag alone led to an increase in the length of the embryo and fetus in comparison with the negative control by 9.9-18.5%, and in combination with the selemag by 37.1-41.1% (P <0.001).

The use of bovine recombinant interferon-tau resulted in an increase of the crown-rump length compared to intact animals by 53.7-56.9% (P <0.001).

Thus, the use of progestamag, follymag in combination with selemag and interferon-tau had the greatest influence on the morphometric indicators of the corpus luteum of pregnancy and the size of the embryo and fetus, respectively, 33.1-44.1% and 35.8-56.8% more than intact animals.
Noted changes in the period of early embryogenesis when biologically active preparations are used by animals ultimately reflected on the state of the newborn young cattle (Table 4).

After progesterone was used, weakness of labor, retention of afterbirth, acute subinvolution of the uterus and acute postpartum endometritis and the incidence of diarrhea in calves were diagnosed 1.3 times less than in the negative control. At the same time, no significant differences were found in the fetal weight in cows of the experimental and control groups.

In cows, after using a prolonged agent, progestamag, the retention of the placenta, acute subinvolution of the uterus and acute endometritis are diagnosed 1.5 times less frequently, compared to animals from the negative control group. The fetal weight obtained from cows treated with progestamag is 10.1% more than that produced from intact animals, with a decrease in cases of diarrhea by 1.75 times.

After the combined use of follymag and selenium, the pathology of the parturation and the postpartum period was diagnosed 1.3-2.0 times less, while the number of cases of diarrhea in calves was reduced by 4.0 times. The fetal weight obtained from these cows is 15.3% (P <0.05) more compared to the negative control.

Triple application of bovine recombinant interferon-tau is accompanied by the absence of cases of parturition pathology and reduction of the pathology of the postpartum functional and inflammatory period by 1.5-3.0 times. The mass of fetuses born from cows after being treated with interferons is 9.8% more than in the negative control, with a reduction in the diagnostics of diarrhea syndrome in them by 3.0 times.

**CONCLUSION**

Thus, the syndrome of delayed embryo development is recorded on average in 36.7%, and intrauterine death - in 18.5% of fertilized animals.

The most effective ways of preventing disorders of early embryogenesis (fetal death, embryo and fetal growth retardation syndrome) are the use of progestogenic and gonadotropic drugs, as well as interferon-series drugs - interferon-tau. The prophylactic efficacy of progestamag was 60.0%, follymag combined with selemag 61.5%, and bovine recombinant interferon-tau 66.7%.

The use of progestamag, bovine recombinant interferon-tau, or the combined use of follymag and selenium helps to reduce the incidence of intrauterine embryo death by 1.5-1.8 times compared with the negative control and the embryo-fetal growth retardation syndrome - 3.0-3.7 times. Pregnancy after the application of these funds proceeds against the background of increased content of progesterone (higher by 16.4-52.2%), which favorably affects the development of the embryo and fetus, the length of which in the first two months of gestation is 35.8-56.9% more than intact animals.

The use of a prolonged progestamag for the prevention of disorders of embryonic development is accompanied by a certain weakening of the inflammatory reaction, a decrease in endogenous intoxication and an increase in the activity of the antioxidant system; the combined use of the gonadotropic drug follymag and selenium containing agent selemag - by activating the indices of the general nonspecific resistance of the organism of pregnant animals; triple application of bovine recombinant interferon-tau - activation of the enzymatic and non-enzymatic antioxidant defense, humoral and cellular link of the body’s natural resistance while reducing the processes of lipid peroxidation and endogenous intoxication of the organism.

**ACKNOWLEDGEMENTS**

This paper was financially supported by the Ministry of Education and Science of the Russian Federation on the program to improve the competitiveness of Peoples’ Friendship University of Russia (RUDN University) among the world’s leading research and education centers in the 2016-2020.
We declare that authors have no competing interests.

**AUTHORS CONTRIBUTION**

The authors contributed equally.

**REFERENCES**